Johnson & Johnson (NYSE:JNJ) Price Target Raised to $220.00 at Stifel Nicolaus

Johnson & Johnson (NYSE:JNJ) had its price objective raised by equities researchers at Stifel Nicolaus from $205.00 to $220.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 0.86% from the stock’s current price.

Several other brokerages have also commented on JNJ. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $193.00 to $208.00 and gave the stock a “market perform” rating in a research note on Friday, January 9th. Royal Bank Of Canada set a $240.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, December 17th. Raymond James Financial increased their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Finally, Wolfe Research lifted their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $215.24.

Johnson & Johnson Trading Down 0.0%

Shares of JNJ stock opened at $218.12 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market capitalization of $525.52 billion, a PE ratio of 21.05, a PEG ratio of 2.24 and a beta of 0.34. The stock has a fifty day simple moving average of $207.39 and a two-hundred day simple moving average of $188.27. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $220.11.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting analysts’ consensus estimates of $2.46. The firm had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Johnson & Johnson

A number of large investors have recently bought and sold shares of the company. Abich Financial Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the third quarter worth $26,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson in the second quarter valued at about $27,000. Clayton Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $28,000. Semmax Financial Advisors Inc. lifted its holdings in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares in the last quarter. Finally, GFG Capital LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $35,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 results and 2026 outlook beat/raised — Revenue of $24.56B topped estimates and J&J issued FY2026 guidance above consensus, underpinning management’s view of sustained mid-single-digit growth. Business Wire: Q4 & Full-Year 2025 Results
• Positive Sentiment: MedTech and oncology drivers — Management called out MedTech operational sales growth and strength in oncology (e.g., Darzalex), supporting margin expansion and recurring revenue upside. PYMNTS: Product launches & regulatory approvals drive growth
• Positive Sentiment: Dividend strength and buy-side sentiment — J&J remains a Dividend King with a ~2.4% yield and healthy payout metrics; analysts maintain a constructive consensus rating (Moderate Buy). Fool: Dividend King profile AmericanBankingNews: Moderate Buy Consensus
• Positive Sentiment: Technical/trend view — Some analysts flag a trend-following buy signal after the earnings-driven pullback, suggesting a lower-risk entry for continuation of the prior rally. MarketBeat: Trend-following signal
• Neutral Sentiment: Management commentary and call materials available — CFO and executives reiterated execution on innovation and strategy in interviews and the earnings call; read the transcript for details on segment dynamics. YouTube: CFO interview Seeking Alpha: Earnings call transcript
• Negative Sentiment: Talc litigation advancing — A court allowed plaintiffs to present expert testimony on general causation in the talc MDL, keeping legal and settlement risk in focus for investors. GlobeNewswire: Talc MDL update
• Negative Sentiment: Stelara biosimilar pressure and profit-taking — Stelara sales declined sharply after losing patent protection; investors are factoring biosimilar competition and some profit-taking after JNJ’s large 2025 share gains, which helped cause a post-report pullback. Blockonomi: Stock reaction & Stelara impact

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.